Editas Medicine, Inc. (EDIT) — Analyst outlook / Analyst consensus target is. Based on 25 analyst ratings, the consensus is bullish — 14 Buy, 9 Hold, 2 Sell.
The consensus price target is $6.00, representing an upside of 77% from the current price $3.39.
Analysts estimate Earnings Per Share (EPS) of $-2.70 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.88 vs est $-2.70 (missed -6.6%). 2025: actual $-1.80 vs est $-1.98 (beat +9%). Analyst accuracy: 92%.
EDIT Stock — 12-Month Price Forecast
$6.00
▲ +76.99% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Editas Medicine, Inc., the price target is $6.00.
The average price target represents a +76.99% change from the last price of $3.39.
EDIT Analyst Ratings
Buy
Based on 25 analysts giving stock ratings to Editas Medicine, Inc. in the past 3 months
EPS Estimates — EDIT
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.88
vs Est –$2.70
▼ 6.2% off
2025
Actual –$1.80
vs Est –$1.98
▲ 9.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — EDIT
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.032B
vs Est $0.034B
▼ 6.3% off
2025
Actual $0.041B
vs Est $0.024B
▲ 40.4% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
